Prevention of calcineurin inhibitor nephrotoxicity in renal transplantation

Transplant Immunology

Volumn 20, Issue 1-2, 2008, Pages 29-31

  Jacquet, A ^a   Francois, H ^a   Frangie, C ^a   Ahmad, L ^a   Charpentier, B ^a   Durrbach, A ^a  

^a IFRNT   (France)

Author keywords

Calcineurin inhibitors; Drug minimization; Nephrotoxicity; Renal function

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ARTICLE; BLOOD TOXICITY; CHRONIC ALLOGRAFT NEPHROPATHY; DRUG WITHDRAWAL; DYSLIPIDEMIA; HISTORY; HUMAN; HYPERTENSION; KIDNEY ALLOGRAFT REJECTION; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; NEPHROTOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS;

ANTIBODIES, MONOCLONAL; CALCINEURIN; CYCLOSPORINE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; TACROLIMUS;

EID: 56049126712     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2008.09.002     Document Type: Article

References (40)

1. Nankivell B.J., Borrows R.J., Fung C.L., O'Connell P.J., Allen R.D., and Chapman J.R. The natural history of chronic allograft nephropathy. N Engl J Med 349 (2003) 2326-2333
2. Liptak P., and Ivanyi B. Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts. Nat Clin Pract Nephrol 2 (2006) 398-404 quiz following 404
3. Cauduro R.L., Costa C., Lhulier F., Garcia R.G., Cabral R.D., Goncalves L.F., et al. Endothelin-1 plasma levels and hypertension in cyclosporine-treated renal transplant patients. Clin Transplant 19 (2005) 470-474
4. Perico N., Dadan J., and Remuzzi G. Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J Am Soc Nephrol 1 (1990) 76-83
5. Conger J.D., Kim G.E., and Robinette J.B. Effects of ANG II, ETA, and TxA2 receptor antagonists on cyclosporin A renal vasoconstriction. Am J Physiol 267 (1994) F443-F449
6. Darlametsos I.E., and Varonos D.D. Role of prostanoids and endothelins in the prevention of cyclosporine-induced nephrotoxicity. Prostaglandins Leukot Essent Fatty Acids 64 (2001) 231-239
7. Pichler R.H., Franceschini N., Young B.A., Hugo C., Andoh T.F., Burdmann E.A., et al. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 6 (1995) 1186-1196
8. Campistol J.M., Inigo P., Jimenez W., Lario S., Clesca P.H., Oppenheimer F., et al. Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Kidney Int 56 (1999) 714-719
9. Inigo P., Campistol J.M., Lario S., Piera C., Campos B., Bescos M., et al. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 12 (2001) 822-827
10. Ozdemir B.H., Ozdemir F.N., Demirhan B., and Haberal M. TGF-beta1 expression in renal allograft rejection and cyclosporine A toxicity. Transplantation 80 (2005) 1681-1685
11. Buetler T.M., Cottet-Maire F., Krauskopf A., and Ruegg U.T. Does cyclosporin A generate free radicals?. Trends Pharmacol Sci 21 (2000) 288-290
12. Justo P., Lorz C., Sanz A., Egido J., and Ortiz A. Intracellular mechanisms of cyclosporin A-induced tubular cell apoptosis. J Am Soc Nephrol 14 (2003) 3072-3080
13. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 15 (2004) 1-12
14. Roos-van Groningen M.C., Scholten E.M., Lelieveld P.M., Rowshani A.T., Baelde H.J., Bajema I.M., et al. Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies. J Am Soc Nephrol 17 (2006) 881-888
15. Kasiske B.L., Chakkera H.A., Louis T.A., and Ma J.Z. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 11 (2000) 1910-1917
16. Johnson R.W., Kreis H., Oberbauer R., Brattstrom C., Claesson K., and Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72 (2001) 777-786
17. Gonwa T.A., Hricik D.E., Brinker K., Grinyo J.M., and Schena F.P. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 74 (2002) 1560-1567
18. Webster A.C., Lee V.W., Chapman J.R., and Craig J.C. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 81 (2006) 1234-1248
19. Oberbauer R., Segoloni G., Campistol J.M., Kreis H., Mota A., Lawen J., et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 18 (2005) 22-28
20. Schrama Y.C., Joles J.A., van Tol A., Boer P., Koomans H.A., and Hene R.J. Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients. Transplantation 69 (2000) 376-383
21. Thervet E., Morelon E., Ducloux D., Bererhi L., Noel L.H., Janin A., et al. Cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion. Clin Transplant 14 (2000) 561-566
22. Abramowicz D., Manas D., Lao M., Vanrenterghem Y., Del Castillo D., Wijngaard P., et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 74 (2002) 1725-1734
23. Smak Gregoor P.J., de Sevaux R.G., Ligtenberg G., Hoitsma A.J., Hene R.J., Weimar W., et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 13 (2002) 1365-1373
24. Schnuelle P., van der Heide J.H., Tegzess A., Verburgh C.A., Paul L.C., van der Woude F.J., et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 13 (2002) 536-543
25. Hazzan M., Labalette M., Copin M.C., Glowacki F., Provot F., Pruv F.R., et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. J Am Soc Nephrol 16 (2005) 2509-2516
26. Nashan B., Curtis J., Ponticelli C., Mourad G., Jaffe J., and Haas T. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 78 (2004) 1332-1340
27. Vitko S., Tedesco H., Eris J., Pascual J., Whelchel J., Magee J.C., et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 4 (2004) 626-635
28. Tedesco-Silva Jr. H., Vitko S., Pascual J., Eris J., Magee J.C., Whelchel J., et al. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 20 (2007) 27-36
29. Etienne I., et al. Benefit of a 50% reduction of cyclosporin exposure in stable kidney transplant recipients treated with MMF without corticosteroids. The DICAM randomized study. Am J Transplant (2007) (Abstract)
30. Ekberg H., Tedesco-Silva H., Demirbas A., Vitko S., Nashan B., Gurkan A., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357 (2007) 2562-2575
31. Grinyo J.M., and Cruzado J.M. Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transplant 6 (2006) 1991-1999
32. Durrbach A., Rostaing L., Tricot L., Ouali N., Wolf P., Pouteil-Noble C., et al. Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor. Transplantation 85 (2008) 486-490
33. Vincenti F., Larsen C., Durrbach A., Wekerle T., Nashan B., Blancho G., et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353 (2005) 770-781
34. Muthukumar T., Dadhania D., Ding R., Snopkowski C., Naqvi R., Lee J.B., et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 353 (2005) 2342-2351
35. Brouard S., Ashton-Chess J., and Soulillou J.P. Surrogate markers for the prediction of long-term outcome in transplantation: Nantes Actualité Transplantation (NAT) 2007 meeting report. Hum Immunol 69 (2008) 2-8
36. Martinez-Llordella M., Puig-Pey I., Orlando G., Ramoni M., Tisone G., Rimola A., et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 7 (2007) 309-319
37. Brouard S., Mansfield E., Braud C., Li L., Giral M., Hsieh S.C., et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A 104 (2007) 15448-15453
38. Mansour H., Homs S., Desvaux D., Badoual C., Dahan K., Matignon M., et al. Intragraft levels of Foxp3 mRNA predict progression in renal transplants with borderline change. J Am Soc Nephrol (2008)
39. Mytilineos J., Laux G., and Opelz G. Relevance of IL10, TGFbeta1, TNFalpha, and IL4Ralpha gene polymorphisms in kidney transplantation: a collaborative transplant study report. Am J Transplant 4 (2004) 1684-1690
40. Creput C., Le Friec G., Bahri R., Amiot L., Charpentier B., Carosella E., et al. Detection of HLA-G in serum and graft biopsy associated with fewer acute rejections following combined liver-kidney transplantation: possible implications for monitoring patients. Hum Immunol 64 (2003) 1033-1038